Endothelin receptor antagonism in pulmonary arterial hypertension – a role for selective ET_A inhibition?

References

• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425–36
   PubMed Web of Science ®Google Scholar
• Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5S–12S
   Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115: 343–9
   Google Scholar
• Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81
   Google Scholar
• Cohen M, Edwards WD, Fuster V. Regression in thromboembolic type of primary pulmonary hypertension during 2½ years of antithrombotic therapy. J Am Coll Cardiol 1986;7: 172–5
   Google Scholar
• Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26:194–201
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485–91
   PubMed Web of Science ®Google Scholar
• Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663–5
   PubMed Web of Science ®Google Scholar
• Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218–22
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895–900
   PubMed Web of Science ®Google Scholar
• Hill NS. Pulmonary Hypertension Therapy. Summit Publications. In press
   Google Scholar
• Lee SH, Channick RN. Endothelin antagonism in pulmonary arterial hypertension. Semin Respir Crit Care Med 2005;26: 402–8
   PubMed Web of Science ®Google Scholar
• Hickey KA, Rubanyi G, Paul RJ, et al. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985;248(5 Pt 1):C550–6
   Google Scholar
• Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 2003;108:2184–90
   PubMed Web of Science ®Google Scholar
• Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434–40
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–15
   PubMed Web of Science ®Google Scholar
• Alberts GF, Peifley KA, Johns A, et al. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994;269:10112–18
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227–37
   Google Scholar
• Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation is an important site for both clearance and production of endothlin-1. Circulation 1996;94:1578–84
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732–9
   PubMed Web of Science ®Google Scholar
• Wagner OF, Vierhapper H, Gasic S, et al. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest 1992;22:277–82
   PubMed Web of Science ®Google Scholar
• Hosoda K, Nakao K, Hiroshi A, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991;287:23–6
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Nakao K, Arai H, et al. Molecular cloning of a nonisopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 1991;178:248–55
   PubMed Web of Science ®Google Scholar
• Seo B, Oemar BS, Siebenmann R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994;89:1203–8
   PubMed Web of Science ®Google Scholar
• Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J 1995;9:1196–204
   PubMed Web of Science ®Google Scholar
• Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91:1367–73
   PubMed Web of Science ®Google Scholar
• de Nucci G, Thomas R, D’Orleans-Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988;85: 9797–800
   Google Scholar
• Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752–6
   PubMed Web of Science ®Google Scholar
• Niwa Y, Nagata N, Oka M, et al. Production of nitric oxide from endothelial cells by 31-amino-acid-length endothelin-1, a novel vasoconstrictive product by human chymase. Life Sci 2000;67:1103–9
   PubMed Web of Science ®Google Scholar
• Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996;81: 1510–15
   Google Scholar
• Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199:1461–5
   PubMed Web of Science ®Google Scholar
• McCulloch KM, Docherty C, MacLean MR. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. Br J Pharmacol 1998;123:1621–30
   Google Scholar
• MacLean MR, McCulloch KM, Baird M. Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6C and on inherent tone in rat pulmonary arteries. J Cardiovasc Pharmacol 1995;26: 822–30
   Google Scholar
• McCulloch KM, MacLean MR. EndothelinB receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat. J Cardiovasc Pharmacol 1995;26(Suppl 3):S169–76
   PubMedGoogle Scholar
• Dupuis J, Jasmin JF, Prie S, et al. Importance of local production of endothelin-1 and of the ET(B) receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther 2000;13:135–40
   PubMed Web of Science ®Google Scholar
• Langleben D, Dupuis J, Langleben I, et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hyper-tension. Chest 2006;129:689–95
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119–23
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346: 896–903
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244–9
   PubMed Web of Science ®Google Scholar
• Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43:1089–115
   PubMed Web of Science ®Google Scholar
• Tracleer (bosentan) [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; November 14, 2005
   Google Scholar
• Davenport AP, Battistini B. Classification of endothelin receptors and antagonists in clinical development. Clin Sci (Lond) 2002;103\(Suppl 48):1S–3S
   Google Scholar
• Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997;40:1690–7
   PubMed Web of Science ®Google Scholar
• Weber C, Schmitt R, Birnboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 1996;60: 124–37
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860–8
   PubMed Web of Science ®Google Scholar
• Davie NJ, Coyne TC, Dixon R. Sitaxsentan: update on basic science studies and clinical trials supporting selective endothelin ETA receptor antagonism in the treatment of pulmonary arterial hypertension. Drugs Fut 2005;30:1283–94
   Google Scholar
• Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441–7
   PubMed Web of Science ®Google Scholar
• Langleben D, Brock T, Dixon R, et al.; STRIDE 1 study group. Effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol 2004;44:S80–4
   Google Scholar
• Galie N, Manes A, Farahani KV, et al. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus 2005;14:713–17
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049–56
   PubMed Web of Science ®Google Scholar
• Benza R, Frost A, Girgis R, et al. Chronic treatment of pulmonary arterial hypertension (PAH) with sitaxsentan and bosentan [Abstract]. Paper presented at American Thoracic Society, 2006; San Francisco, CA
   Google Scholar
• Highland KB, Strange C, Girgis R, et al. Comparison of sitaxsentan and bosentan in pulmonary arterial hypertension associated with connective tissue diseases. Paper presented at EULAR 2006: 7th Annual European Congress of Rheumatology, June 21–24, 2006, Amsterdam, The Netherlands
   Google Scholar
• Vatter H, Zimmermann M, Jung C, et al. Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery. Clin Sci (Lond) 2002;103\(Suppl 48):408S–13S
   Google Scholar
• Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46: 529–35
   PubMed Web of Science ®Google Scholar
• Olschewski H, Galie N, Kramer M, et al.; the ARIES-2 study group. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study [Abstract]. Paper presented at American Thoracic Society, 2006, San Francisco, CA
   Google Scholar
• Mehta S. Sildenafil for pulmonary arterial hypertension: exciting, but protection required. Chest 2003;123:989–92
   PubMed Web of Science ®Google Scholar